Junshi Biosciences’ JS203 Bispecific Antibody Receives NMPA Green Light for NHL Study
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...
Eli Lilly’s Trulicity + Insulin Combo Meets Goals in China’s AWARD-CHN3 Study
Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...
China’s 7th VBP Round Yields 65.5% Drug Price Cuts, Foreign Firms Secure Bids
China’s 7th national volume-based procurement (VBP) round concluded with winning bids averaging a 65.5% price...
CDE Grants Priority Review to Ascentage’s Olerembatinib and Roche’s Crovalimab
The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...
Athenex Sells China Subsidiaries to TiHe Capital for USD 19 Million
US-based Athenex Inc. (Nasdaq: ATNX) announced an agreement to sell all equity interests in its...
Tasly Pharmaceuticals and Mauna Kea Form JV to Commercialize Cellvizio in China
China-based Tasly Pharmaceuticals (SHA: 600535) announced a joint venture (JV) with France’s Mauna Kea Technologies...
MicroPort MedBot’s Honghu Robot Wins FDA 510(k) Certification for Joint Replacement
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that its in-house developed orthopedic surgery...
Venus Medtech’s Transcatheter Prosthetic Pulmonary Valve Approved by NMPA
The National Medical Products Administration (NMPA) has approved Venus Medtech (Hangzhou) Inc’s (HKG: 2500) transcatheter...
Hengrui Medicine’s SHR-1701 + Ameile Combo Greenlit for EGFR-Mutated NSCLC Trial
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that the National Medical Products Administration...
Eucure Biopharma Doses First Patient in YH003 + Keytruda Trial for Mucosal Melanoma
Eucure Biopharma, a subsidiary of Sino-US contract research organization Biocytogen, announced that the first patient...
Overland ADCT BioPharma Launches Global Phase III Trial for Zynlonta in DLBCL
Overland ADCT BioPharma, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC Therapeutics SA...
Bio-Thera Solutions Doses First Patient in BAT8006 Phase I Study for Solid Tumors
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that the first patient has been dosed in a...
Neurophth and Abogen Partner on mRNA Therapy for Retinal Diseases
China-based Neurophth Biotechnology Ltd, a gene therapy specialist, has partnered with compatriot mRNA drug developer...
Hong Kong Researchers Explore TES for Depression and Alzheimer’s Treatment
Researchers at The University of Hong Kong’s Li Ka Shing Faculty of Medicine (HKUMed) and...
CASI Pharmaceuticals Invests in Precision Immune Therapeutics for CID-103 Development
US-based CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced the completion of a financing round for China’s...
Sinopharm in Talks to Acquire BBI Life Sciences in USD 1B+ Deal
China National Pharmaceutical Group Co., Ltd (Sinopharm) is reportedly considering a bid to acquire Shanghai-based...
Acer Therapeutics and Relief Therapeutics Awarded China Patent for ACER-001
US-based Acer Therapeutics Inc. (Nasdaq: ACER) and Swiss partner Relief Therapeutics Holding SA (SWX: RLF)...
Bangbang Robot Raises USD 14.9M in Series B to Expand Mobility Tech
Shanghai-based Bangbang Robot Co., Ltd, a developer of assisted mobility technology, has raised nearly RMB...
OBI Pharma Halts OBI 888 Trial Over Manufacturing Costs, Shifts Focus to Globo H ADC
Taiwan-based OBI Pharma (TPEx: 4174) announced the discontinuation of a Phase I/II trial for its...
Hengrui Medicine’s SHR8554 Accepted for NMPA Review in Postoperative Pain
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its market filing for SHR8554,...